Pathstone Holdings LLC Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Pathstone Holdings LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,325 shares of the medical research company's stock after selling 6,280 shares during the quarter. Pathstone Holdings LLC's holdings in Amgen were worth $24,070,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Beck Mack & Oliver LLC grew its holdings in shares of Amgen by 0.7% during the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock worth $1,205,000 after purchasing an additional 34 shares during the last quarter. Blossom Wealth Management grew its holdings in shares of Amgen by 3.5% during the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after purchasing an additional 37 shares during the last quarter. Zullo Investment Group Inc. grew its holdings in shares of Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after buying an additional 37 shares during the last quarter. Trillium Asset Management LLC grew its holdings in shares of Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after buying an additional 37 shares during the last quarter. Finally, Evermay Wealth Management LLC grew its holdings in shares of Amgen by 1.5% during the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock worth $691,000 after buying an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Finally, Piper Sandler reduced their price objective on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $310.18.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $0.72 on Friday, hitting $272.41. The company's stock had a trading volume of 2,588,369 shares, compared to its average volume of 2,792,425. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market capitalization of $146.48 billion, a price-to-earnings ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a 50 day moving average of $291.00 and a 200-day moving average of $288.09.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same period last year, the company posted $3.96 EPS. The company's revenue was up 9.4% on a year-over-year basis. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.49%. Amgen's dividend payout ratio (DPR) is 86.86%.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 8,711 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now directly owns 62,147 shares of the company's stock, valued at $18,222,743.34. This trade represents a 12.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.76% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.